April 26, 2023 — Insights surface when we take the time to listen to people living with obesity. Yesterday, Ro and the Obesity Action Coalition released results from a study of the thoughts and feelings people are having about obesity, weight loss, and the new GLP-1 medicines. There’s a lot to think about in these results – about motivations […]
April 3, 2023 — This is a merger that has taken decades – the merger of obesity and diabetes. Ethan Sims first coined the term diabesity in 1973. Even five decades ago, the coincidence of diabetes and obesity was unmistakable, but the standards of care for obesity and diabetes did not reflect the recognition of obesity as anything other […]
March 8, 2023 — We would classify this as a report of a side effect. But it’s not really an adverse event. It seems that for some people, the use of semaglutide has prompted less alcohol use. In the New York Times, Dani Blum describes the experience of one patient: “In August 2022, Eva Monsen’s endocrinologist prescribed Ozempic [semaglutide] […]
December 5, 2022 — Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]
November 16, 2022 — It’s a fact. Media needs your attention. Thus, journalistic standards live in in tension with the temptation for sensational headlines that trivialize a subject like obesity. We’ve seen it before. Yet the current crop of sensational headlines offering a twisted understanding of serious new obesity treatments is especially disappointing. Here’s an example from the supposedly […]
October 31, 2022 — One of the themes you will hear when ObesityWeek gets underway tomorrow in San Diego is the dramatic progress that’s coming into view with new obesity drugs. But the picture quickly becomes murky in the real world because of issues with supply and access to these new and improved obesity meds. The access to care […]
October 15, 2022 — In GQ recently, Will Peischel asked if the world is ready for extremely effective weight-loss drugs. Of course, the simple answer is yes and no. First of all, it’s clear enough that most people don’t really understand these drugs or the condition they treat. Peischel makes that clear right up front when he calls them […]
May 14, 2020 — Yesterday the process of a slow reveal began. Novo Nordisk released the first pivotal results in studies of semaglutide for obesity. This new drug, already available for diabetes, has potential to bring us closer to truly effective obesity treatment without surgery. This was merely a first glimpse – topline results from only one of four […]
June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]
December 27, 2018 — How safe is a drug for type 2 diabetes that causes weight gain? This question pops up as we read a big new study of outcomes with second line drugs for type 2 diabetes. That’s because two types of drugs that cause weight gain – basal insulin and sulfonylureas – had a clear link to bad […]
